Enteral human serum immunoglobulin treatment of cryptosporidiosis in mice with severe combined immunodeficiency

Abstract

The anti-cryptosporidial immunoglobulin G antibodies in two commercially available human serum immunoglobulin (HSIG) products were quantified and characterized. The mean level of Cryptosporidium parvum-specific immunoglobulin G in HSIG was eightfold higher than the antibody level found in the sera of three immunocompetent individuals convalescing from cryptosporidiosis. However, HSIG products displayed no reactivity to cryptosporidial antigens in immunoblot analyses, while convalescent-phase sera demonstrated characteristic banding patterns. When HSIG was given to newborn severe combined immunodeficiency (scid) mice before and shortly after experimental infection, a decreased intensity of infection was observed in the intestines of the mice compared with that of control mice. However, there was no difference in mortality or histopathologic findings in the intestines of HSIG-treated and control mice when treatment was not started until 22 days of age. These results indicate that HSIG may be beneficial when given prophylactically; however, HSIG cannot eradicate cryptosporidia from mucosal surfaces in an established infection.

Severe cryptosporidiosis in a seven‐year‐old renal transplant recipient – Case report and review of the literature

“…A few case reports have suggested that hyperimmune bovine colostrum may modify the disease course of Cryptosporidium infection in immunocompromised hosts (38, 39). Other therapies include passive immunization via human breast milk or oral human immunoglobulin (40–42). However, these have been studied only in observational studies or in vitro assays.…”